{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:04:52Z","timestamp":1790935492475,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Once-weekly alendronate 70 mg and once-weekly risedronate 35 mg are indicated for the treatment of postmenopausal osteoporosis. These two agents were compared in a 12-month head-to-head trial. Greater gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability.<\/jats:p>\n               <jats:p>Introduction: The nitrogen-containing bisphosphonates, alendronate and risedronate, are available in once-weekly (OW) formulations for the treatment of postmenopausal osteoporosis. A 12-month, head-to-head study was performed to compare these agents in the treatment of postmenopausal women with low BMD.<\/jats:p>\n               <jats:p>Materials and Methods: A total of 1053 patients from 78 U.S. sites were randomized to OW alendronate 70 mg (N = 520) or risedronate 35 mg (N = 533), taken in the morning after fasting. Endpoints included BMD changes over 6 and 12 months at the hip trochanter, total hip, femoral neck, and lumbar spine (LS); percent of patients with predefined levels of change in trochanter and LS BMD at 12 months; and change in biochemical markers of bone turnover at 3, 6, and 12 months. Tolerability was evaluated by adverse experience (AE) reporting.<\/jats:p>\n               <jats:p>Results: Significantly greater increases in hip trochanter BMD were seen with alendronate (3.4%) than risedronate (2.1%) at 12 months (treatment difference, 1.4%; p &amp;lt; 0.001) as well as 6 months (treatment difference, 1.3%; p &amp;lt; 0.001). Significantly greater gains in BMD were seen with alendronate at all BMD sites measured (12-month difference: total hip, 1.0%; femoral neck, 0.7%; LS, 1.2%). Significant differences were seen as early as 6 months at all sites. A greater percentage of patients had \u22650% (p &amp;lt; 0.001) and \u22653% (p &amp;lt; 0.01) gain in trochanter and spine BMD at 12 months with alendronate than risedronate. Significantly greater (p &amp;lt; 0.001) reductions in all biochemical markers of bone turnover occurred with alendronate compared with risedronate by 3 months. No significant differences were seen between treatment groups in the incidence of upper gastrointestinal AEs or AEs causing discontinuation.<\/jats:p>\n               <jats:p>Conclusions: In this 12-month, head-to-head trial of alendronate and risedronate, given in accordance with the approved OW regimens for treatment of osteoporosis in postmenopausal women, alendronate produced greater gains in BMD and greater reductions in markers of bone turnover than risedronate. The greater antiresorptive effect of alendronate was seen as early as 3 months, and the tolerability profiles were similar.<\/jats:p>","DOI":"10.1359\/jbmr.040920","type":"journal-article","created":{"date-parts":[[2007,10,23]],"date-time":"2007-10-23T16:40:36Z","timestamp":1193157636000},"page":"141-151","source":"Crossref","is-referenced-by-count":262,"title":["Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study"],"prefix":"10.1093","volume":"20","author":[{"given":"Clifford J","family":"Rosen","sequence":"first","affiliation":[{"name":"Maine Center of Osteoporosis Research and Education and St Joseph Hospital, Bangor, Maine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C","family":"Hochberg","sequence":"additional","affiliation":[{"name":"University of Maryland Division of Rheumatology, School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney L","family":"Bonnick","sequence":"additional","affiliation":[{"name":"Clinical Research Center of North Texas, Denton, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McClung","sequence":"additional","affiliation":[{"name":"Oregon Osteoporosis Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Broy","sequence":"additional","affiliation":[{"name":"Illinois Bone and Joint Institute, Morton Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Kagan","sequence":"additional","affiliation":[{"name":"Foundation for Osteoporosis Research and Education, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erluo","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Development, Merck & Co., Inc., West Point, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Petruschke","sequence":"additional","affiliation":[{"name":"Clinical Development, Merck & Co., Inc., West Point, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond E","family":"Thompson","sequence":"additional","affiliation":[{"name":"Clinical Development, Merck & Co., Inc., West Point, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E","family":"de Papp","sequence":"additional","affiliation":[{"name":"Clinical Development, Merck & Co., Inc., West Point, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019223775800_bib1","author":"National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"key":"2024013019223775800_bib2","author":"National Osteoporosis Foundation (NOF)"},{"key":"2024013019223775800_bib3","first-page":"72","article-title":"Bone density at various sites for prediction of hip fractures","volume":"341","author":"Cummings","year":"1993","journal-title":"The study of Osteoporotic Fractures Research Group. Lancet"},{"key":"2024013019223775800_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jbmr.5650070607","article-title":"Axial and appendicular bone density predict fractures in older women","volume":"7","author":"Black","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s001980050100","article-title":"Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women","volume":"8","author":"Garnero","year":"1998","journal-title":"The EPIDOS prospective study. Osteoporos Int"},{"key":"2024013019223775800_bib6","first-page":"10","article-title":"Biochemical markers of bone turnover and fracture prediction","volume":"9","author":"Hannon","year":"2003","journal-title":"J Br Menopause Soc"},{"key":"2024013019223775800_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0378-5122(03)00042-2","article-title":"Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women","volume":"44","author":"Bruyere","year":"2003","journal-title":"Maturitas"},{"key":"2024013019223775800_bib8","first-page":"2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures","volume":"280","author":"Cummings","year":"1998","journal-title":"Results from the Fracture Intervention Trial. JAMA"},{"key":"2024013019223775800_bib9","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"FIT Research Group. J Clin Endocrinol Metab"},{"key":"2024013019223775800_bib10","first-page":"83","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int"},{"key":"2024013019223775800_bib11","first-page":"1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA"},{"key":"2024013019223775800_bib12","first-page":"1246","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Fracture Intervention Trial Research Group. Arthritis Rheum"},{"key":"2024013019223775800_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib17","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019223775800_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019223775800_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"2024013019223775800_bib20","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/sim.984","article-title":"A method to assess the proportion of treatment effect explained by a surrogate endpoint","volume":"20","author":"Li","year":"2001","journal-title":"Stat Med"},{"key":"2024013019223775800_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","article-title":"Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint","volume":"23","author":"Marcus","year":"2002","journal-title":"Endocr Rev"},{"key":"2024013019223775800_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","article-title":"Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy","volume":"34","author":"Delmas","year":"2004","journal-title":"Bone"},{"key":"2024013019223775800_bib23","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Alendronate Once-Weekly Study Group. Aging (Milano)"},{"key":"2024013019223775800_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2024013019223775800_bib25","first-page":"1371","article-title":"Users' Guides to the Medical Literature: XIX","volume":"282","author":"McAlister","year":"1999","journal-title":"Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA"},{"key":"2024013019223775800_bib26","first-page":"771","article-title":"Users' Guides to the Medical Literature: XIX","volume":"282","author":"Bucher","year":"1999","journal-title":"Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints. Evidence-based medicine working group. JAMA"},{"key":"2024013019223775800_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomized placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"2024013019223775800_bib28","first-page":"2095","volume-title":"Physicians' Desk Reference","author":"Anonymous","year":"2002","edition":"56th ed."},{"key":"2024013019223775800_bib29","volume-title":"Physicians' Desk Reference","author":"Anonymous","year":"2002","edition":"56th ed."},{"key":"2024013019223775800_bib30","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1359\/jbmr.2003.18.10.1789","article-title":"Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib31","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J","article-title":"Some comments on frequently used multiple endpoint adjustment methods in clinical trials","volume":"16","author":"Sankoh","year":"1997","journal-title":"Stat Med"},{"key":"2024013019223775800_bib32","first-page":"508","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev"},{"key":"2024013019223775800_bib33","first-page":"517","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev"},{"key":"2024013019223775800_bib34","first-page":"570","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev"},{"key":"2024013019223775800_bib35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF02652563","article-title":"Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women","volume":"7","author":"Liu","year":"1997","journal-title":"Osteoporos Int"},{"key":"2024013019223775800_bib36","first-page":"S48","article-title":"The precision of PA spine, DualFemur\u00ae and single femur bone density studies on the GE Lunar Prodigy, a DXA fan-array device","volume":"5","author":"Bonnick","year":"2002","journal-title":"J Clin Densitom"},{"key":"2024013019223775800_bib37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/art.1780380706","article-title":"Radiographic osteoarthritis of the hip and bone mineral density","volume":"38","author":"Nevitt","year":"1995","journal-title":"The Study of Osteoporotic Fractures Research Group. Arthritis Rheum"},{"key":"2024013019223775800_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"Importance of precision in bone density measurements","volume":"4","author":"Bonnick","year":"2001","journal-title":"J Clin Densitom"},{"key":"2024013019223775800_bib39","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1359\/jbmr.2001.16.12.2163","article-title":"Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture","volume":"16","author":"Chesnut","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib40","first-page":"164","volume-title":"Osteoporosis","author":"Parfitt","year":"1993"},{"key":"2024013019223775800_bib41","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib43","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"2024013019223775800_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biochemical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2024013019223775800_bib46","first-page":"402","article-title":"Sustained effect of risedronate: A 7-year study in postmenopausal women","volume":"72","author":"Sorensen","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2024013019223775800_bib47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1359\/JBMR.0301228","article-title":"Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses","volume":"19","author":"Delmas","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019223775800_bib48","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2307\/2670067","article-title":"Review of a solution to the ecological inference problem","volume":"93","author":"Freedman","year":"1998","journal-title":"J Am Stat Assoc"},{"key":"2024013019223775800_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s001980200052","article-title":"Uncertain future of trials in osteoporosis","volume":"13","author":"Kanis","year":"2002","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.040920","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/1\/141\/56478242\/5650200119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/1\/141\/56478242\/5650200119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:07:34Z","timestamp":1710342454000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/1\/141-151\/7593147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040920","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,1,1]]},"published":{"date-parts":[[2005,1,1]]}}}